<DOC>
	<DOCNO>NCT02956850</DOCNO>
	<brief_summary>This sponsor-open , investigator- participant-blinded , multi-center study ass safety , tolerability , pharmacokinetics pharmacodynamics RO7020531 healthy participant participant chronic hepatitis B . Part I conduct two portion : Single Ascending Dose ( SAD ) Multiple Ascending Dose ( MAD ) include healthy volunteer . Part II commence completion MAD portion Part I include Chronic Hepatitis B ( CHB ) participant .</brief_summary>
	<brief_title>A Study Healthy Volunteers Participants With Chronic Hepatitis B Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Multiple Doses RO7020531</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Part 1 : SAD MAD Healthy Volunteers A Body Mass Index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) , inclusive Nonsmokers , use le ( &lt; ) 10 cigarette ( equivalent nicotinecontaining product ) per day Negative AntiNuclear Antibody ( ANA ) test ; positive dilution great 1:40 associated history symptom potential connective tissue disease immunemediated disease Part 2 : CHB Participants A BMI 18 32 kg/m^2 , inclusive CHB infection ( positive test Hepatitis B surface antigen [ HBsAg ] 6 month prior randomization ) HBsAg detectable screen Hepatitis B Virus ( HBV ) deoxyribonucleic acid ( DNA ) &lt; 90 international unit per milliliter ( IU/mL ) least 6 month prior randomization ; HBV DNA &lt; 90 IU/mL screen Roche Cobas assay Negative ANA test ; positive dilution great 1:40 associated history symptom potential connective tissue disease immunemediated disease Liver biopsy , fibroscanÂ® equivalent elastography test obtain within 6 month prior randomization demonstrate liver disease consistent chronic HBV infection absence cirrhosis absence extensive bridging fibrosis ( cirrhosis extensive bridge fibrosis define great equal ( &gt; /= ) Metavir 3 , recommend cutoff fibroscan 8.5 kilopascals [ kPa ] ) On treatment tenofovir , entecavir , adefovir , telbivudine , either single agent combination , least 6 month Part 1 : SAD MAD Healthy Volunteers History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune haemolytic anemia , scleroderma , severe psoriasis , rheumatoid arthritis , multiple sclerosis , autoimmune disease ) ; clinically significant thyroid disease , psychiatric disease , acute infection ( e.g. , influenza ) , gastrointestinal ( GI ) disease ( include inflammatory bowel disease , peptic ulcer disease , GI hemorrhage ) Any clinically significant concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion Investigator , pose unacceptable risk participant study Positive Hepatitis A virus antibody ( HAV Ab IgM ) , HBsAg , Hepatitis C antibody ( HCV Ab ) , positive human immunodeficiency virus ( HIV ) screen History clinically significant thyroid disease ; also , participant clinically significant elevate thyroidstimulating hormone ( TSH ) concentration screen Positive result antimitochondrial antibody ( AMA ) , antismooth muscle antibody ( ASMA ) thyroid peroxidase antibody Part 2 : CHB Participants History liver cirrhosis History evidence bleed esophageal varix Decompensated liver disease ( e.g. , ChildPugh Class B C clinical classification clinical evidence ascites varix ) History evidence medical condition associate chronic liver disease HBV infection ( e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure , thalassemia , nonalcoholic steatohepatitis , etc . ) Documented history evidence metabolic liver disease within one year randomization Positive test Hepatitis A virus ( IgM antiHAV ) , HCV , Hepatitis D HIV History suspicion hepatocellular carcinoma alpha fetoprotein &gt; /=13 nanogram per milliliter ( ng/mL ) screen History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune haemolytic anemia , scleroderma , severe psoriasis , rheumatoid arthritis , multiple sclerosis , autoimmune disease ) ; clinically significant thyroid disease , psychiatric disease , acute infection ( e.g. , influenza ) , GI disease ( include inflammatory bowel disease , peptic ulcer disease , GI hemorrhage ) History organ transplantation Clinically significant thyroid disease ; also , participant clinically significant elevate TSH concentration screen Positive result AMA , ASMA thyroid peroxidase antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>